cbdMD's Oasis line of hemp-derived beverages is now available in South Carolina through a new distribution agreement with Morales Beverage Group, South Carolina, a beverage statewide alcohol distributor. The rollout includes the full Oasis portfolio.

7/9 09:01

cbdMD Partners with Denver Audubon for Conservation

cbdMD through its Bluebird Botanicals brand announced an official partnership with Denver Audubon, a Colorado-based conservation organization. "Bluebird has always stood for more than products," said Ronan Kennedy, CEO and CFO of cbdMD. "The brand was built on a connection to nature, trust, and responsible wellness. Partnering with Denver Audubon allows us to bring those values to life by supporting conservation, education, and wildlife stewardship in Colorado."

6/16 10:31

cbdMD Appoints Wade Brown as Chief Marketing Officer

cbdMD announced the appointment of Wade Brown as Chief Marketing Officer. "Brown joined cbdMD in March 2025 and has been central to stabilizing the Company's brand portfolio and supporting its acquisition of Bluebird Botanicals. Most recently, cbdMD reported 19% year-over-year and 12% sequential revenue growth, supported by continued momentum in its core brands and the integration of Bluebird. Prior to joining cbdMD, Brown held senior marketing and growth leadership roles across a range of consumer brands, including NatureWise, Vanity Planet, Inc Authority, First Tactical, Noble Outfitters, and Kevin's Naturals. His experience spans dietary supplements, beauty, online services, and omnichannel CPG, with deep expertise in ecommerce, Amazon, performance marketing, and brand portfolio growth," the company stated.

12/19 15:30

cbdMD Enters Securities Purchase Agreements Issuing 1M Convertible Preferred Shares

cbdMD announced that it has entered into securities purchase agreements with institutional investors whereby company issued the investors an aggregate of 1M shares of Series C convertible preferred stock in consideration of gross proceeds to the company of $2.25M. The company intends to use the net proceeds of approximately $2.1M for working capital general corporate purposes and support ongoing strategic initiatives. The Series C shares have a 10% annual dividend and are convertible at the option of the holder into the company's common stock at an initial conversion price of $2.25 per share, subject to certain anti-dilution protection provisions, with rights and preferences substantially the same as the company's issued and outstanding Series B convertible preferred stock.

12/19 15:30

cbdMD Trading Resumes

cbdMD trading resumes

Show More Events

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.